Defunct Company
Total Trials
27
As Lead Sponsor
14
As Collaborator
13
Total Enrollment
4,940
NCT00132626
Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
Phase: Phase 2
Role: Collaborator
Start: Sep 30, 1992
Completion: Aug 31, 2005
NCT00129675
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
Start: Feb 28, 2003
Completion: May 31, 2009
NCT00117195
A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease
Phase: N/A
Start: May 31, 2003
Completion: Jan 31, 2012
NCT00200447
An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)
Role: Lead Sponsor
Start: Mar 31, 2004
Completion: Sep 30, 2004
NCT00273351
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
Start: Jan 31, 2006
Completion: Jan 31, 2008
NCT00315250
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
Completion: Jun 30, 2010
NCT00287248
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
Phase: Phase 1
Start: Feb 28, 2006
Completion: Mar 31, 2008
NCT00316797
Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects
Start: Apr 30, 2006
Completion: Jan 31, 2014
NCT00397228
ALTROPANE® SPECT Imaging in Patients With Parkinson Disease
Start: Nov 30, 2006
Completion: Dec 31, 2011
NCT00387075
A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease
Completion: Aug 31, 2023
NCT00427674
Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients
Start: Jan 31, 2007
Completion: Oct 31, 2009
NCT00439010
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
Start: Feb 28, 2007
NCT00448799
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
Start: Mar 31, 2007
NCT00456417
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
Start: Apr 30, 2007
Completion: Dec 31, 2007
NCT00470925
Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects
Start: May 31, 2007
Completion: Feb 29, 2008
NCT00544453
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
Start: Oct 31, 2007
Completion: Jul 31, 2008
NCT00657813
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
Start: Mar 31, 2008
Completion: Sep 30, 2008
NCT01217021
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
Phase: Early Phase 1
Start: Sep 30, 2010
Completion: Mar 31, 2011
NCT01859767
Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
Start: Apr 30, 2013
Completion: Apr 30, 2015
NCT02103894
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Start: Feb 28, 2014
Completion: Sep 30, 2016
NCT02370524
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
Start: Jan 31, 2015
Completion: Jan 31, 2016
NCT02531360
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
Start: May 31, 2015
Completion: Aug 31, 2016
NCT03876002
Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET
Start: Jun 28, 2016
Completion: Feb 7, 2018
NCT03080051
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Start: Aug 31, 2016
Completion: Mar 6, 2017
NCT03058965
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Start: Nov 29, 2016
Completion: May 11, 2018
NCT03082768
Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
Start: Mar 3, 2017
Completion: Mar 1, 2018
NCT03142724
Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects
Start: May 1, 2017